HTN Practice Pt2 Flashcards

1
Q

amlodipine

A

norvasc -dhp ccb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

nifedipine er

A

procardia - dhp ccb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

diltiazem

A

cardizem - non dhp ccb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

aliskiren

A

tekturna - diirect renin inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

bisoprolol

A

zebata - cardioselective beta blockers (beta 1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

metoprolol succinate

A

toprol - cardioselective beta blocker (beta 1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

carvedilol

A

coreg - alpha/beta blocker (beta 1 and 2, alpha 1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

dhp ccb moa

A

inhibits calcium ions from entering slow channels of vascular smooth muscle- leading to vasodilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

dhp ccb contraindications

A

none

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

dhp ccb adr

A

peripheral edema, pulmonary edema, hepatotoxicity, thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

dhp ccb ddi

A

major substrate of CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

dhp ccb notes

A

immediate release nifedipine has increased risk of mi and mortality- only er is used, can take up to one week to see bp lowering effects- no electrolyte changes, major substrate of cyp3a4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

non dhp ccb moa

A

inhibits calcium from entering vascular smooth muscle and myocardium, slowing av node/hr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

non dhp ccb contraindications

A

2nd or 3rd degree heart block

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

non dhp ccb adr

A

peripheral edema, pulmonary ede3ma, ha, heart failure, heart block, hepatotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

non dhp ccb ddi

A

major substrate of CYP3A4, moderate inhibitor of CYP3A4- worse with verapamil than dilt

16
Q

non dhp ccb notes

A

cyp3a4 major substrate and moderate inhibitor (dose adjustments for lovastatin/simvastatin), avoid use in patients with hfref, avoid routine use with beta blockers, multiple brands exist, following timing for administration (dilt only), some brands are capsules that can be opened and sprinkled on food (dilt only)

17
Q

amlodipine dosing

A

norvasc is normally dosed at 2.5-10 mg daily

18
Q

nifedipine er dosing

A

procardia is dosed at 30-120 mg daily

19
Q

diltiazem dosing

A

cardizem is dosed at 120-360 mg daily

20
Q

beta blocker moa

A

inhibiting beta 1 (all) and beta2(some) to decrease hr and myocardial contractility- variable inhibition based on selectivity

21
Q

beta blocker contraindication

A

severe bradycardia
precaution: with copd disease

22
Q

beta blocker adr

A

dizziness, fatigue, reduced exercise tolerance, bronchospasm, insomnia, impotence

23
Q

beta blocker ddi

A

additive av nodal blockage with non dhp ccb

24
Q

beta blocker notes

A

avoid abrupt withdrawal- can cause rebound tachycardia, angina, and mi, patients may feel fatigued when starting- this will go away with time, may mask feelings of low blood glucose, use with caution in patients with severe bronchospastic disease, can enhance hypoglycemic effects of insulin and sulfonylureas

25
Q

bisoprolol dosing

A

zebata is usually dosed at 2.5-10mg daily
cardioselective

26
Q

metoprolol succinate dosing

A

toprol xl is dosed at 50-200 mg daily
cardioselective

27
Q

carvedilol dosing

A

coreg is dosed at 12.5-50 mg in 2 divded doses
combined alpha and beta selectivity

28
Q

direct renin inhibitor notes

A

do not use raas drugs in combination., long half life, lack of long term studies on cv outcomes, high drug costs, electrolyte impact

29
Q

aliskiren dosing

A

tekturna is dosed at 150-300 mg daily